Pemvidutide vs tirzepatide: how do they compare?

What exactly is pemvidutide, and how does it differ from tirzepatide?

Tirzepatide activates two receptors simultaneously (GIP and GLP-1) both of which influence appetite, gastric emptying and blood-glucose regulation. It is the only dual-agonist weight-loss medicine currently licensed in the UK, approved under the brand name Mounjaro. The full picture on Mounjaro, including how it works and who it is licensed for, is worth reading if this is your first encounter with the drug.

Pemvidutide takes a different approach. It is a GLP-1 and glucagon dual agonist — the second receptor here is glucagon rather than GIP. Glucagon raises energy expenditure and promotes fat breakdown through the liver, which is a mechanistically distinct lever from the GIP pathway tirzepatide pulls. Early trial data suggest pemvidutide may preserve lean muscle mass to a greater degree than some GLP-1 medicines, which is an active area of research interest. However, these findings come from phase-2 studies with relatively small participant numbers, and no head-to-head trial against tirzepatide has been published as of mid-2026.

Pemvidutide is developed by Altimmune and remains in clinical trials. It carries no MHRA marketing authorisation for weight loss, is not available through any UK pharmacy for this indication, and cannot be prescribed for weight management through a regulated UK service at this time.

What does the weight-loss evidence look like for each?

For tirzepatide, the evidence base is substantial. SURMOUNT-1 (a phase-3 randomised controlled trial of 2,539 adults with obesity) reported an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks, as published in the New England Journal of Medicine. SURMOUNT-5 then compared tirzepatide directly with semaglutide 2.4mg and found tirzepatide produced greater average weight reduction over the same period. NICE reviewed this body of evidence and recommended tirzepatide for eligible adults in England, see NICE technology appraisal TA1026 for the full criteria.

Pemvidutide's phase-2 data showed meaningful weight loss over 24–48 weeks, with some analyses suggesting proportionally less loss of lean mass compared with semaglutide. Those results are genuinely interesting to researchers. But a 24-week phase-2 study is not the same kind of evidence as a 72-week phase-3 trial in thousands of participants, and no regulatory body has yet reviewed pemvidutide's phase-3 package, because it does not yet exist.

If you are reading comparison pieces on emerging medicines because you feel frustrated by how slowly NHS access moves, that frustration is understandable. But the honest answer is that phase-2 promise does not always survive phase-3 scrutiny.

Can I access pemvidutide in the UK right now?

No. Pemvidutide is not approved by the MHRA for any indication. It cannot legally be prescribed or dispensed as a weight-loss medicine through any regulated UK pharmacy, including ours. Pages or sellers claiming otherwise should be treated with significant scepticism, a medicine offered for sale without a valid UK marketing authorisation and without a proper prescription represents a serious safety risk. The MHRA's guidance on verifying online pharmacies is a useful starting point if you have concerns about a supplier; you can check any registered pharmacy at the GPhC online register.

Tirzepatide, by contrast, is available now through a regulated private prescription route. Our clinical team (led by our GPhC-registered prescribers) reviews every consultation personally. For context on what private treatment currently costs, the Mounjaro cost page covers pricing honestly, including what the Eli Lilly list-price changes in September 2025 meant for private patients.

If you are curious about other pipeline or comparator medicines being set against tirzepatide, the retatrutide comparison and the mazdutide comparison follow the same evidence-first approach.

Which medicine is right for me?

That is precisely the question a prescriber works through with you, not something a comparison article can answer. Tirzepatide's eligibility criteria under its UK licence cover adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The prescriber also looks at your medical history, current medications and whether any contraindications apply, all of which the NHS guidance on weight-management injections covers for context.

Pemvidutide may become a genuine option at some point if its phase-3 programme succeeds and the MHRA grants a licence, but that is a future possibility, not a present one. Our weight-loss treatment overview covers the medicines we currently prescribe and why each is chosen for different clinical profiles, and if you want to understand how tirzepatide sits alongside similar agents, our page on tirzepatide vs Mounjaro clarifies the relationship between the active ingredient and the branded medicine, while our comparison of reta vs tirzepatide sets out how another pipeline drug measures up against it. Which suits you is a decision our prescribers make with you, based on your health, not a league table.